Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing and lunch

157P - Comparison of Survival Outcomes in Young Patients with Breast Cancer Receiving Contralateral Prophylactic Mastectomy Versus Unilateral Mastectomy

Date

12 May 2023

Session

Poster viewing and lunch

Presenters

Hong bo Huang

Citation

Annals of Oncology (2023) 8 (1suppl_4): 101221-101221. 10.1016/esmoop/esmoop101221

Authors

H.B. Huang

Author affiliations

  • Chongqing Medical University, Chongqing/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 157P

Background

Contralateral prophylactic mastectomy (CPM) has been performed for several decades in patients with unilateral breast cancer (BC). However, the survival benefits of CPM are controversial, particularly in young women.

Methods

The clinical data of 69,000 young female patients (age ≤ 40 years) who were diagnosed to have unilateral BC and underwent UM or CPM between January 1, 2000 and December 31, 2019 were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. The following patients were excluded from the final analysis: age > 40 years, male, those with unconfirmed pathological diagnosis, those with bilateral BC, those lacking SEER cause-specific death classification, those lacking months of survival data, and those with uncertainty regarding UM or CPM.Propensity score matching (PSM) was performed between the CPM and UM groups. The overall survival (OS) rate and BC-specific survival (BCSS) rate were determined for both groups.

Results

A total of 36528 patients (21600 and 14928 patients in the UM and CPM groups, respectively) were included in this study. The mean (SD) age of follow-up was 35.5 (4.0) years. The relative rate of CPM increased from 12.3% in 2000 to 55.7% in 2013 and then gradually decreased to 47.4% in 2019. After PSM, 13089 patients remained in each group. The CPM group showed a higher 5-year OS rate (82.1% vs. 75.8%) and a higher 5-year BCSS rate (83.5% vs. 77.7%) than the UM group. Multivariate Cox proportional hazards regression analysis showed that CPM significantly decreased 25% risk of all-cause mortality (OS, hazard ratio [HR]: 0.75, 95% confidence interval [CI]: 0.70–0.80, P < 0.001) and 25% risk of BC-specific mortality (BCSS, HR: 0.75, 95% CI: 0.70–0.80; P < 0.001) in young BC patients as compared to UM. Almost consistent results were observed in subgroup analyses based on different TNM stages, molecular subtypes, race, tumor grade, marital status, radiotherapy status, and chemotherapy status, except for some.

Conclusions

This study suggests that CPM improved OS and BCSS benefits in young BC patients as compared to UM. Randomized clinical trials with a larger sample size are required in the future to confirm these results.

Editorial acknowledgement

The authors would like to thank the anonymous reviewers for their insightful suggestions and careful reading of the manuscript.

Legal entity responsible for the study

Chong Qing Medical University.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.